Benefits of specialist palliative care by identifying active ingredients of service composition, structure, and delivery model: A systematic review with meta-analysis and meta-regression.

IF 15.8 1区 医学 Q1 Medicine PLoS Medicine Pub Date : 2024-08-02 eCollection Date: 2024-08-01 DOI:10.1371/journal.pmed.1004436
Miriam J Johnson, Leah Rutterford, Anisha Sunny, Sophie Pask, Susanne de Wolf-Linder, Fliss E M Murtagh, Christina Ramsenthaler
{"title":"Benefits of specialist palliative care by identifying active ingredients of service composition, structure, and delivery model: A systematic review with meta-analysis and meta-regression.","authors":"Miriam J Johnson, Leah Rutterford, Anisha Sunny, Sophie Pask, Susanne de Wolf-Linder, Fliss E M Murtagh, Christina Ramsenthaler","doi":"10.1371/journal.pmed.1004436","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Specialist palliative care (SPC) services address the needs of people with advanced illness. Meta-analyses to date have been challenged by heterogeneity in SPC service models and outcome measures and have failed to produce an overall effect. The best service models are unknown. We aimed to estimate the summary effect of SPC across settings on quality of life and emotional wellbeing and identify the optimum service delivery model.</p><p><strong>Methods and findings: </strong>We conducted a systematic review with meta-analysis and meta-regression. Databases (Cochrane, MEDLINE, CINAHL, ICTRP, clinicaltrials.gov) were searched (January 1, 2000; December 28, 2023), supplemented with further hand searches (i.e., conference abstracts). Two researchers independently screened identified studies. We included randomized controlled trials (RCTs) testing SPC intervention versus usual care in adults with life-limiting disease and including patient or proxy reported outcomes as primary or secondary endpoints. The meta-analysis used, to our knowledge, novel methodology to convert outcomes into minimally clinically important difference (MID) units and the number needed to treat (NNT). Bias/quality was assessed via the Cochrane Risk of Bias 2 tool and certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. Random-effects meta-analyses and meta-regressions were used to synthesize endpoints between 2 weeks and 12 months for effect on quality of life and emotional wellbeing expressed and combined in units of MID. From 42,787 records, 39 international RCTs (n = 38 from high- and middle-income countries) were included. For quality of life (33 trials) and emotional wellbeing (22 trials), statistically and clinically significant benefit was seen from 3 months' follow-up for quality of life, standardized mean difference (SMD in MID units) effect size of 0.40 at 13 to 36 weeks, 95% confidence interval (CI) [0.21, 0.59], p < 0.001, I2 = 60%). For quality of life at 13 to 36 weeks, 13% of the SPC intervention group experienced an effect of at least 1 MID unit change (relative risk (RR) = 1.13, 95% CI [1.06, 1.20], p < 0.001, I2 = 0%). For emotional wellbeing, 16% experienced an effect of at least 1 MID unit change at 13 to 36 weeks (95% CI [1.08, 1.24], p < 0.001, I2 = 0%). For quality of life, the NNT improved from 69 to 15; for emotional wellbeing from 46 to 28, from 2 weeks and 3 months, respectively. Higher effect sizes were associated with multidisciplinary and multicomponent interventions, across settings. Sensitivity analyses using robust MID estimates showed substantial (quality of life) and moderate (emotional wellbeing) benefits, and lower number-needed-to-treat, even with shorter follow-up. As the main limitation, MID effect sizes may be biased by relying on derivation in non-palliative care samples.</p><p><strong>Conclusions: </strong>Using, to our knowledge, novel methods to combine different outcomes, we found clear evidence of moderate overall effect size for both quality of life and emotional wellbeing benefits from SPC, regardless of underlying condition, with multidisciplinary, multicomponent, and multi-setting models being most effective. Our data seriously challenge the current practice of referral to SPC close to death. Policy and service commissioning should drive needs-based referral at least 3 to 6 months before death as the optimal standard of care.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"21 8","pages":"e1004436"},"PeriodicalIF":15.8000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329153/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1371/journal.pmed.1004436","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Specialist palliative care (SPC) services address the needs of people with advanced illness. Meta-analyses to date have been challenged by heterogeneity in SPC service models and outcome measures and have failed to produce an overall effect. The best service models are unknown. We aimed to estimate the summary effect of SPC across settings on quality of life and emotional wellbeing and identify the optimum service delivery model.

Methods and findings: We conducted a systematic review with meta-analysis and meta-regression. Databases (Cochrane, MEDLINE, CINAHL, ICTRP, clinicaltrials.gov) were searched (January 1, 2000; December 28, 2023), supplemented with further hand searches (i.e., conference abstracts). Two researchers independently screened identified studies. We included randomized controlled trials (RCTs) testing SPC intervention versus usual care in adults with life-limiting disease and including patient or proxy reported outcomes as primary or secondary endpoints. The meta-analysis used, to our knowledge, novel methodology to convert outcomes into minimally clinically important difference (MID) units and the number needed to treat (NNT). Bias/quality was assessed via the Cochrane Risk of Bias 2 tool and certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. Random-effects meta-analyses and meta-regressions were used to synthesize endpoints between 2 weeks and 12 months for effect on quality of life and emotional wellbeing expressed and combined in units of MID. From 42,787 records, 39 international RCTs (n = 38 from high- and middle-income countries) were included. For quality of life (33 trials) and emotional wellbeing (22 trials), statistically and clinically significant benefit was seen from 3 months' follow-up for quality of life, standardized mean difference (SMD in MID units) effect size of 0.40 at 13 to 36 weeks, 95% confidence interval (CI) [0.21, 0.59], p < 0.001, I2 = 60%). For quality of life at 13 to 36 weeks, 13% of the SPC intervention group experienced an effect of at least 1 MID unit change (relative risk (RR) = 1.13, 95% CI [1.06, 1.20], p < 0.001, I2 = 0%). For emotional wellbeing, 16% experienced an effect of at least 1 MID unit change at 13 to 36 weeks (95% CI [1.08, 1.24], p < 0.001, I2 = 0%). For quality of life, the NNT improved from 69 to 15; for emotional wellbeing from 46 to 28, from 2 weeks and 3 months, respectively. Higher effect sizes were associated with multidisciplinary and multicomponent interventions, across settings. Sensitivity analyses using robust MID estimates showed substantial (quality of life) and moderate (emotional wellbeing) benefits, and lower number-needed-to-treat, even with shorter follow-up. As the main limitation, MID effect sizes may be biased by relying on derivation in non-palliative care samples.

Conclusions: Using, to our knowledge, novel methods to combine different outcomes, we found clear evidence of moderate overall effect size for both quality of life and emotional wellbeing benefits from SPC, regardless of underlying condition, with multidisciplinary, multicomponent, and multi-setting models being most effective. Our data seriously challenge the current practice of referral to SPC close to death. Policy and service commissioning should drive needs-based referral at least 3 to 6 months before death as the optimal standard of care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过确定服务组成、结构和提供模式的有效成分来确定专科姑息关怀的益处:荟萃分析和荟萃回归的系统综述。
背景:专业姑息关怀(SPC)服务可满足晚期患者的需求。迄今为止的荟萃分析受到了 SPC 服务模式和结果衡量标准异质性的挑战,未能产生整体效果。最佳服务模式尚不可知。我们的目的是估算 SPC 在不同环境下对生活质量和情绪健康的总体影响,并确定最佳的服务模式:我们通过荟萃分析和荟萃回归进行了系统回顾。我们对数据库(Cochrane、MEDLINE、CINAHL、ICTRP、clinicaltrials.gov)进行了检索(2000 年 1 月 1 日;2023 年 12 月 28 日),并辅以进一步的人工检索(即会议摘要)。两名研究人员独立筛选了已确定的研究。我们纳入的随机对照试验(RCT)对患有局限生命疾病的成人进行了 SPC 干预与常规护理的对比测试,并将患者或代理报告的结果作为主要或次要终点。据我们所知,荟萃分析采用了新颖的方法将结果转换为最小临床重要性差异(MID)单位和治疗所需人数(NNT)。偏倚/质量通过 Cochrane Risk of Bias 2 工具进行评估,证据的确定性通过建议评估、发展和评价分级(GRADE)工具进行评估。随机效应荟萃分析和荟萃回归用于综合 2 周至 12 个月的终点,以 MID 单位表示和合并对生活质量和情绪健康的影响。从 42,787 条记录中,纳入了 39 项国际 RCT(n = 38 项来自高收入和中等收入国家)。在生活质量(33 项试验)和情绪健康(22 项试验)方面,从 3 个月的随访来看,生活质量具有统计学和临床意义上的显著益处,13 至 36 周的标准化平均差(SMD,以 MID 为单位)效应大小为 0.40,95% 置信区间 (CI) [0.21, 0.59],P < 0.001,I2 = 60%)。在 13 至 36 周的生活质量方面,13% 的 SPC 干预组出现了至少 1 个 MID 单位的变化(相对风险 (RR) = 1.13,95% CI [1.06, 1.20],P < 0.001,I2 = 0%)。在情绪健康方面,16% 的患者在 13 至 36 周内至少经历了 1 个 MID 单位的变化(95% CI [1.08, 1.24],P < 0.001,I2 = 0%)。在生活质量方面,NNT 从 69 降至 15;在情绪健康方面,2 周和 3 个月的 NNT 分别从 46 降至 28。在各种情况下,多学科干预和多成分干预的效果更显著。使用稳健的 MID 估计值进行的敏感性分析表明,即使随访时间较短,也能获得实质性(生活质量)和中度(情绪健康)益处以及较低的治疗所需人数。作为主要局限性,MID效应大小可能会因为依赖于非姑息治疗样本的推导而产生偏差:据我们所知,我们采用了新颖的方法将不同的结果结合在一起,发现了明确的证据表明,无论基础病症如何,SPC对生活质量和情绪健康的总体影响大小适中,其中多学科、多成分和多设置模式最为有效。我们的数据对目前临近死亡时转诊至 SPC 的做法提出了严峻挑战。政策和服务委托应推动基于需求的转诊,至少在死亡前 3 到 6 个月进行转诊,以此作为最佳护理标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
PLoS Medicine
PLoS Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
17.60
自引率
0.60%
发文量
227
审稿时长
4-8 weeks
期刊介绍: PLOS Medicine is a prominent platform for discussing and researching global health challenges. The journal covers a wide range of topics, including biomedical, environmental, social, and political factors affecting health. It prioritizes articles that contribute to clinical practice, health policy, or a better understanding of pathophysiology, ultimately aiming to improve health outcomes across different settings. The journal is unwavering in its commitment to uphold the highest ethical standards in medical publishing. This includes actively managing and disclosing any conflicts of interest related to reporting, reviewing, and publishing. PLOS Medicine promotes transparency in the entire review and publication process. The journal also encourages data sharing and encourages the reuse of published work. Additionally, authors retain copyright for their work, and the publication is made accessible through Open Access with no restrictions on availability and dissemination. PLOS Medicine takes measures to avoid conflicts of interest associated with advertising drugs and medical devices or engaging in the exclusive sale of reprints.
期刊最新文献
Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. Economic, cultural, and social inequalities in potentially inappropriate medication: A nationwide survey- and register-based study in Denmark. The critical need for a robust research agenda on ultra-processed food consumption and cancer risk. The NOVA system can be used to address harmful foods and harmful food systems. Identification and outcomes of acute kidney disease in patients presenting in Bolivia, Brazil, South Africa, and Nepal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1